Ahmedabad: Sentynl Therapeutics Inc (Sentynl), a US-based biopharmaceutical company which is also wholly owned by Ahmedabad-headquartered Zydus Lifesciences, recently closed its acquisition of global proprietary rights for Zokinvy. Zokinvy is the first and only USFDA-approved treatment to target the cause and symptoms of progeria in people older than 12 months. Progeria is an ultra-rare, fatal, genetic premature aging disease which accelerates mortality in young patients. After its USFDA approval in 2020, Zokinvy secured approval in the European Union and Great Britain (2022) and Japan (Jan 2024). Zydus has thus expanded its portfolio of medicines for rare diseases. “This acquisition marks an important milestone in growing our portfolio of medicines for rare and orphan diseases, which can have devastating consequences if left untreated. We are focused on supporting patients to live healthier and more fulfilled lives,” said Matt Heck, president & CEO, Sentynl. Audrey Gordon, president and executive director of Progeria Research Foundation (PRF) said, “Without Zokinvy therapy, children with progeria die of the same heart disease that affects millions . Zokinvy gives these beautiful children longer, healthier lives.”
We also published the following articles recently
Zydus biopharma arm acquires global proprietary rights for Progeria treatment
Sentynl Therapeutics Inc, owned by Zydus Lifesciences, acquired global rights for Zokinvy, the first US FDA-approved treatment for ultra-rare genetic premature aging diseases. Zokinvy obtained USFDA approval in 2020 and expanded globally by 2024.
Timely detection, treatment key for Fabry disease patients
Dr. Arvind Chabra, a Fabry patient, emphasizes the importance of timely intervention and awareness. Lysosomal Storage Disorder Support Society stresses the need for education about this genetic disorder, impacting 1 in 40,000 people.
Zydus to exit Bayer joint venture
Bayer acquires 25% stake in JV, Bayer Zydus Pharma, for Rs 282 crore, gradually moving to full ownership over 13 years. Leveraging strengths, the joint venture succeeds in serving the fast-growing domestic market.
